Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

35.340
-1.380-3.76%
Volume:18.34M
Turnover:648.44M
Market Cap:214.30B
PE:32.58
High:36.620
Open:36.060
Low:35.000
Close:36.720
52wk High:43.939
52wk Low:27.882
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.06
T/O Rate:0.30%
Dividend:0.49
Dividend Rate:1.40%
EPS(LYR):1.085
ROE:19.40%
ROA:9.08%
PB:4.86
PE(LYR):32.58
PS:11.56

Loading ...

Hansoh Pharma's HS-20136-2 Injection Receives NMPA Approval for Clinical Trials

Stock News
·
Jul 02

Hansoh Pharma Says China NMPA Clears Hs-20136-2 Injection for Clinical Trials in Type 2 Diabetes

Reuters
·
Jul 02

Hansoh Pharmaceutical - Clinical Trial Approvals for Hs-20136-2 Injection Issued- by Nmpa

THOMSON REUTERS
·
Jul 02

Hansoh Pharmaceutical Group Stock Rises 6.4% in Hong Kong

Dow Jones
·
Jul 02

Movement Alert|Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally

Market Focus
·
Jul 02

Hansoh Pharmaceutical Group Stock Falls 2.3% in Hong Kong

Dow Jones
·
Jun 30

Movement Alert|Hansoh Pharmaceutical Falls 3.03% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure

Market Focus
·
Jun 30

Hansoh Pharmaceutical Group Stock Rises 5.8% in Hong Kong

Dow Jones
·
Jun 29

Movement Alert|Hansoh Pharmaceutical Rises 4.88% in Regular Trading, Pharma Sector Rally Combines with Dense Pipeline Catalysts

Market Focus
·
Jun 29

Hansoh Pharma Shareholders Approved 2026 Share Scheme at AGM

Reuters
·
Jun 26

Hansoh Pharmaceutical Group Stock Slides 1.3% in Hong Kong

Dow Jones
·
Jun 24

Movement Alert|Hansoh Pharmaceutical Rises 3.18% in Regular Trading, Receives Inaugural Buy Rating from Guosheng Securities

Market Focus
·
Jun 24

Hansoh Pharmaceutical Group (SEHK:3692) Stock Could Be Below Fair Value After Hang Seng Index Inclusion

Simply Wall St.
·
Jun 21

Hansoh Pharma releases in vitro study data on HS-20094 dual-biased GLP-1/GIP agonist at ENDO 2026

Reuters
·
Jun 16

Hansoh Pharmaceutical Group Stock Rallies 2.6% in Hong Kong

Dow Jones
·
Jun 12

Hansoh Pharma posts 80% MMR at week 48 in phase 1b HS-10382 plus flumatinib trial for newly diagnosed CML-CP

Reuters
·
Jun 12

Hansoh Pharmaceutical Group (SEHK:3692) Valuation Check After Hang Seng China Enterprises Index Inclusion

Simply Wall St.
·
Jun 11

Hansoh Pharma Appoints Guo Ying as Joint Company Secretary Following Zhong Shengli’s Resignation

Bulletin Express
·
Jun 10

Hansoh Pharma’s NDA for HS-10568 Injection Accepted by China’s NMPA

Bulletin Express
·
Jun 10

HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection

Stock News
·
Jun 10